Hypertension and stable coronary artery disease: An overview

Journal of Cardiovascular Medicine

Volumn 14, Issue 8, 2013, Pages 545-552

  Pedrinelli, Roberto ^a   Ballo, Piercarlo ^b   Fiorentini, Cesare ^c   Galderisi, Maurizio ^d   Ganau, Antonello ^e   Germanò, Giuseppe ^f   Innelli, Pasquale ^d   Paini, Anna ^g   Perlini, Stefano ^h   Salvetti, Massimo ^g   Zacà, Valerio ⁱ  

^a UNIVERSITY OF PISA   (Italy)

^b SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF SASSARI   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY OF BRESCIA   (Italy)

^h UNIVERSITY OF PAVIA   (Italy)

ⁱ UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Antihypertensive treatment; Inducible ischaemia; Stable coronary artery disease; Systemic hypertension

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NIFEDIPINE; TRANDOLAPRIL; VERAPAMIL;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL EVALUATION; CLINICAL PRACTICE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EXERCISE TEST; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LONG TERM CARE; LONG TERM EXPOSURE; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; RELAPSE; REVIEW; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS ECHOCARDIOGRAPHY; SYSTOLIC HEART FAILURE; THORAX PAIN; TRANSLUMINAL CORONARY ANGIOPLASTY; UNCERTAINTY;

ANGINA PECTORIS; ANTIHYPERTENSIVE AGENTS; CORONARY DISEASE; ECHOCARDIOGRAPHY, STRESS; HUMANS; HYPERTENSION;

EID: 84880052298     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283609332     Document Type: Review

References (72)

1. Kannel WB. Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res 1995; 18: 181-196.
2. Pedrinelli R, Ballo P, Fiorentini C, et al., Gruppo di Studio Ipertensione e Cuore, Societa' Italiana di Cardiologia. Hypertension and acute myocardial infarction: an overview. J Cardiovasc Med (Hagerstown) 2012; 13:194-202.
3. Daly C, Clemens F, Lopez-Sendon JL, et al., Euro Heart Survey Investigators. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J 2006; 27:1298-1304. (Pubitemid 43998102)
4. Bangalore S, Steg G, Deedwania P, et al., REACH Registry Investigators. b-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012; 308: 1340-1349.
5. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin- convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
6. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788. (Pubitemid 37093919)
7. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al., INVEST Investigators. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816. (Pubitemid 37509488)
8. Nissen SE, Tuzcu EM, Libby P, et al., CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2225.
9. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-convertingenzyme inhibition in stable coronary artery disease. The PEACE Trial investigators. N Engl J Med 2004; 351: 2058-2068.
10. Poole-Wilson PA, Lubsen J, Kirwan BA, et al., Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849-857.
11. Boden WE,O'Rourke RA, Teo KK, et al., COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-1516. (Pubitemid 46588415)
12. Fox K, Ford I, Steg PG, et al., BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-816.
13. Yusuf S, Teo KK, Pogue J, et al., ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. (Pubitemid 351522739)
14. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372: 1174-1183.
15. Marzilli M, Merz CN, Boden WE, et al. Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link!. J Am Coll Cardiol 2012; 60: 951-956.
16. Senior R, Basu S, Handler C, et al. Diagnostic accuracy of dobutamine stress echocardiography for detection of coronary heart disease in hypertensive patients. Eur Heart J 1996; 17: 289-295. (Pubitemid 26118274)
17. Elhendy A, van Domburg RT, Sozzi FB, et al. Impact of hypertension on the accuracy of exercise stress myocardial perfusion imaging for the diagnosis of coronary artery disease. Heart 2001; 85: 655-661. (Pubitemid 32973462)
18. Picano E, Lucarini AR, Lattanzi F, et al. Dipyridamole-echocardiography in essential hypertensive patients with chest pain. Hypertension 1988; 12: 238-243.
19. Pasierski T, Szwed H, Malczewska B, et al. Advantages of exercise echocardiography in comparison to dobutamine echocardiography in the diagnosis of coronary artery disease in hypertensive subjects. J Hum Hypertens 2001; 15: 805-809. (Pubitemid 33054205)
20. Cortigiani L, Bigi R, Rigo F, et al., for the Echo Persantine International Cooperative Study Group. Diagnostic value of exercise electrocardiography and dipyridamole stress echocardiography in hypertensive and normotensive chest pain patients with right bundle branch block. J Hypertens 2003; 21: 2189-2194. (Pubitemid 38296882)
21. Maltagliati A, Berti M, Muratori M, et al. Exercise echocardiography versus exercise electrocardiography in the diagnosis of coronary artery disease in hypertension. Am J Hypertens 2000; 13: 796-801. (Pubitemid 30604118)
22. Lu C, Lu F, Fragasso G, et al. Comparison of exercise electrocardiography, technetium-99m sestamibi single photon emission computed tomography, and dobutamine and dipyridamole echocardiography for detection of coronary artery disease in hypertensive women. Am J Cardiol 2010; 105: 1254-1260.
23. Fragasso G, Lu C, Dabrowski P, et al. Comparison of stress/rest myocardial perfusion tomography, dipyridamole and dobutamine stress echocardiography for the detection of coronary disease in hypertensive patients with chest pain and positive exercise test. J Am Coll Cardiol 1999; 34: 441-447.
24. Astarita C, Palinkas A, Nicolai E, et al. Dipyridamole-atropine stress echocardiography versus exercise SPECT scintigraphy for detection of coronary artery disease in hypertensives with positive exercise test. J Hypertens 2001; 19: 495-502. (Pubitemid 32195386)
25. Elhendy A, Geleijnse ML, van Domburg RT, et al. Comparison of dobutamine stress echocardiography and technetium-99m sestamibi single-photon emission tomography for the diagnosis of coronary artery disease in hypertensive patients with and without left ventricular hypertrophy. Eur J Nucl Med 1998; 25: 69-78. (Pubitemid 28107906)
26. Ariff B, Thom SA, Foale RA, Mayet J. Stress echocardiography for the diagnosis of ischaemia in hypertensives. J Hum Hypertens 2000; 14:399-401. (Pubitemid 30426698)
27. Prisant LM, von Dohlen TW, Houghton JL, et al. A negative thallium (- dipyridamole) stress test excludes significant obstructive epicardial coronary disease in hypertensive patients. Am J Hypertens 1992; 5:71-75.
28. Aggeli C, Christoforatou E, Giannopoulos G, et al. The diagnostic value of adenosine stress-contrast echocardiography for diagnosis of coronary artery disease in hypertensive patients: comparison to Tl-201 single-photon emission computed tomography. Am J Hypertens 2007; 20: 533-538. (Pubitemid 46678701)
29. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary. The task force on the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-1381. (Pubitemid 43998110)
30. Kern MJ. Coronary blood flow and myocardial ischemia. In: Zipes DP, Libby P, Bonow RO, Braunwald E, editors. Braunwald's heart disease: a textbook of cardiovascular medicine. Part VI: Atherosclerotic cardiovascular disease, 7th ed. Philadeliphia, PA: Elsevier Saunders; 2005.
31. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007; 356: 830-840.
32. Hoffman JI. A critical view of coronary reserve. Circulation 1987; 75: I6-11.
33. Rambaldi R, Bigi R, Fiorentini C. Noninvasive techniques to assess myocardial ischemia in hypertensive patients. Future Cardiol 2008; 4: 569-581.
34. Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004; 159: 882-890. (Pubitemid 38657490)
35. Kaptoge S, Di Angelantonio E, Pennells L, et al., Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367: 1310-1320.
36. Cortigiani L, Zanetti L, Bigi R, et al. Safety and feasibility of dobutamine and dipyridamole stress echocardiography in hypertensive patients. J Hypertens 2002; 20: 1423-1429. (Pubitemid 34925688)
37. Koshy S, Thompson RC. Review of radiation reduction strategies in clinical cardiovascular imaging. Cardiol Rev 2012; 20: 139-144.
38. Kelly S, Berry E, Roderick P, et al. The identification of bias in studies of the diagnostic performance of imaging modalities. Br J Radiol 1997; 70: 1028-1035. (Pubitemid 27464204)
39. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med 2010; 362: 886-895.
40. Bugiardini R. Women, 'nonspecific' chest pain, and normal or near-normal coronary angiograms are not synonymous with favourable outcome. Eur Heart J 2006; 27: 1387-1389. (Pubitemid 43998066)
41. Massie BM, Szlachcic Y, Tubau JF, et al. Scintigraphic and electrocardiographic evidence of silent coronary artery disease in asymptomatic hypertension: a case-control study. J Am Coll Cardiol 1993; 22: 1598-1606. (Pubitemid 23336711)
42. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356:2388-2398. (Pubitemid 46883773)
43. Zellweger MJ, Hachamovitch R, Kang X, et al. Threshold, incidence, and predictors of prognostically high-risk silent ischemia in asymptomatic patients without prior diagnosis of coronary artery disease. J Nucl Cardiol 2009; 16: 193-200.
44. Hlatky MA. Framework for evaluating novel risk markers. Ann Intern Med 2012; 156: 468-469.
45. Young LH, Wackers FJ, Chyun DA, et al., DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009; 301: 1547-1555.
46. American Diabetes Association. 2011 Standards of medical care in diabetes. Diabetes Care 2011; 34(Suppl 1):S11-S61.
47. Ferket BS, Genders TS, Colkesen EB, et al. Systematic review of guidelines on imaging of asymptomatic coronary artery disease. J Am Coll Cardiol 2011; 57: 1591-1600.
48. Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
49. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368: 581-588. (Pubitemid 44209181)
50. Pahor M. Nifedipine and other calcium channel blockers. Eur Heart J 1997; 18:168. (Pubitemid 27105788)
51. Deanfield JE, Sellier P, Thaulow E, et al. Potent antiischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering? Eur Heart J 2010; 31: 2650-2659.
52. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335: 1107-1114. (Pubitemid 26330964)
53. Jamerson K, Weber MA, Bakris GL, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
54. Dahlöf B, Sever PS, Poulter NR, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906. (Pubitemid 41265663)
55. Bertrand ME, Ferrari R, Remme WJ, et al., EUROPA Investigators. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J 2010; 159: 795-802.
56. Kubon C, Mistry NB, Grundvold I, et al. The role of beta-blockers in the treatment of chronic heart failure. Trends Pharmacol Sci 2011; 32:206-212.
57. Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-1737. (Pubitemid 29290470)
58. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
59. Lindholm LH, Carlberg B, SamuelssonO. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553. (Pubitemid 41540112)
60. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761-2788. (Pubitemid 46842793)
61. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27:923-934.
62. Cushman WC, Evans GW, Byington RP, et al., ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585.
63. Peralta CA, Norris KC, Li S, et al., KEEP Investigators. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med 2012; 172: 41-47.
64. Boersma E, Keil U, De Bacquer D, et al., EUROASPIRE I and II Study Groups. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003; 21:1831-1840. (Pubitemid 37290101)
65. Leander K, Wiman B, Hallqvist J, et al. Primary risk factors influence risk of recurrent myocardial infarction/death from coronary heart disease: results from the Stockholm Heart Epidemiology Program (SHEEP). Eur J Cardiovasc Prev Rehabil 2007; 14: 532-537. (Pubitemid 47229735)
66. Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27: 1360-1369.
67. Bangalore S, Qin J, Sloan S, et al., PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy- Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation 2010; 122: 2142-2151.
68. Cortigiani L, Bigi R, Landi P, et al. Prognostic implication of stress echocardiography in 6214 hypertensive and 5328 normotensive patients. Eur Heart J 2011; 32: 1509-1518.
69. Velazquez EJ, Lee KL, Deja MA, et al., STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011; 364: 1607-1616.
70. Panza JA, Holly TA, Asch FM, et al. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 2013 [Epub ahead of print]. 10.1016/j.jacc.2013. 02.014.
71. Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: metaanalysis of randomized controlled trials. Arch Intern Med 2012; 172:312-319.
72. Wheatley K, Ives N, Gray R, et al., ASTRAL Investigators. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009; 361: 1953-1962.